{"id":"NCT01948830","sponsor":"Novartis Pharmaceuticals","briefTitle":"Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD","officialTitle":"A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-17","primaryCompletion":"2015-11-19","completion":"2015-11-19","firstPosted":"2013-09-24","resultsPosted":"2016-12-15","lastUpdate":"2017-04-17"},"enrollment":650,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Age-related Macular Degeneration","Choroidal Neovascularization"],"interventions":[{"type":"DRUG","name":"Ranibizumab 0.5mg","otherNames":["Lucentis"]},{"type":"DRUG","name":"Ranibizumab 0.5mg","otherNames":["Lucentis"]}],"arms":[{"label":"Group I ranibizumab 0.5 mg monthly","type":"ACTIVE_COMPARATOR"},{"label":"Group II ranibizumab 0.5 mg TER","type":"ACTIVE_COMPARATOR"}],"summary":"This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration","primaryOutcome":{"measure":"Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12","timeFrame":"Baseline to month 12","effectByArm":[{"arm":"Group I Ranibizumab 0.5 mg TER","deltaMin":6.2,"sd":0.7},{"arm":"Group II Ranibizumab 0.5 mg Monthly","deltaMin":8.1,"sd":0.7}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":91,"countries":["Belgium","Chile","Croatia","Denmark","Egypt","Germany","Hungary","India","Israel","Italy","Portugal","Russia","Slovakia","Slovenia","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["34934034","32374423","31563866"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":323},"commonTop":["Intraocular pressure increased (Study eye)","Nasopharyngitis","Hypertension","Conjunctival haemorrhage (Study eye)","Visual acuity reduced (Study eye)"]}}